论文部分内容阅读
β2-肾上腺素受体激动剂indacaterol(QAB-149)是由诺华制药公司开发的用于治疗哮喘和慢性阻塞性肺病(chronic obstructive pulmonary d isease,COPD)的新药。临床研究表明,本品在哮喘和COPD患者人群中均可被较好地耐受,且比已上市的β2-肾上腺素受体激动剂有更好的心血管安全性
The beta2-adrenergic receptor agonist indacaterol (QAB-149) is a new drug developed by Novartis for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Clinical studies have shown that this product is well tolerated in both asthmatic and COPD patient populations and has better cardiovascular safety than marketed β2-adrenoreceptor agonists